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Background. de novo metastatic breast cancer (dnMBC) is responsible for 6-10% of breast cancer 
presentations with increasing incidence and has remained resistant to detection by mammography 
screening. Recent publications hypothesized that in addition to poor screening uptake, the presentation of 
dnMBC may be due to its unfavourable biology which remains unknown at the molecular level. Here we 
investigated the tumour biology of dnMBC in the form of clinicopathology, genomic alterations and 
differential gene expression to create a comparative landscape of de novo versus relapsed metastatic 
breast cancer (rMBC). Additionally, to address the current screening limitations, we conducted a 
preliminary biomarker investigation for early dnMBC detection. 
Methods. In this retrospective case-control study, gene expression and clinical data were accessed from 
the Cancer Genome Atlas (TCGA) for primary tumours of treatment-naïve patients with dnMBC (n=17), 
rMBC (n=49), and normal tissue (n=113). The clinical and histological data were assessed categorically 
using Fisher’s Exact Test for significance (p<0.05), or continuously using the Mann-Whitney Test 
(p<0.05) where appropriate. The differential gene expression analysis was performed using EdgeR’s 
negative binomial distribution model with a false discovery rate (FDR) <0.05. The resulting gene list was 
analysed manually for roles in metastasis as well as ontologically using STRING-DB with FDR <0.05. 
Results. dnMBCs showed improved median survival vs rMBC (36 vs. 12 months). dnMBCs were more 
likely to be hormone receptor positive, less likely to be triple negative with lower histological 
lymphocytic infiltrate. In terms of genome alterations, dnMBCs had 4-fold increased PTEN mutations 
and poor survival with ABL2 and GATA3 alterations. Expression-wise, dnMBCs down-regulated TNFa, 
IL-17 signalling, and chemotaxis, while up-regulating steroid biosynthesis, cell migration, and cell 
adhesion. Biomarker analysis detected pre-existing and novel breast cancer biomarkers.  
Conclusion. The comparative tumour landscape revealed significant clinical, pathological and molecular 
differences between dnMBC and rMBC, indicating that dnMBC may be a separate biological entity to 
rMBC at the primary level with differing paths to metastasis. Additionally, we provided a list of potential 
serum biomarkers that may be useful in detecting dnMBC in its pre-metastatic window if such a window 
exists. 
 












Breast cancer (BC) is the most common cancer in women with 1.7 million new cases per year, causing 
520 000  cancer-related deaths annually [1]. The incidence of breast cancer is increasing and is estimated 
to reach 3.2 million new cases per year by 2050 [1] With advances in treatment and the introduction of 
screening programs, BC mortality has decreased by 25 – 38%  [2]. However there exists a subpopulation 
of breast cancer patients who present with stage IV or metastatic disease at the time of diagnosis, a 
phenomenon referred to as de novo metastatic or de novo stage IV breast cancer (dnMBC) [3]. Cancer 
screening programs have reduced the incidence of metastasis at diagnosis for other malignancies such as 
prostate cancer by 50% from 1990 to 2010, but similar initiatives for BC have had no effect on dnMBC 
incidence, which is currently at 6%-10% of BC presentations, accounting for 28% of metastatic breast 
disease and increasing [3-6]. This discrepancy in screening outcomes has given rise to avenues of 
investigation into the clinical features of these patients and basic histopathological classification of their 
tumours [3]. Here we present the first clinicomolecular landscape of these tumours and their relapsed 
counterparts (rMBC). 
 
3. Materials and Methods 
3.1 Clinicopathological and gene expression data. The gene expression, genomic alteration, and clinical 
data from treatment-naïve, primary tumours were obtained from the Cancer Genome Atlas (TCGA) and 
cBioPortal [7, 8]. The expression data was processed in the form of high throughput sequencing (HTSeq)  
counts. Patients with dnMBC (n=17) were defined as being diagnosed with Stage IV disease. rMBC 
patients (n=49) were defined as patients diagnosed with Stages I to III disease whose “new tumour event” 
was listed as “Distant Metastasis” greater than 3 months after initial diagnosis to differentiate a true 










biomarker discovery (n=113). Tumour leukocyte infiltrate quantitation was obtained from Satlz et al., 
2018 [9]. Histological data was obtained from Ping et al., 2016 [10]. Mutation and copy number data 
were obtained from TCGA’s PanCancer Atlas.  Clinicopathological data was analysed for statistical 
significance by Fisher’s exact test (p<0.05) or Mann-Whitney U-test (p<0.05) where appropriate. Survival 
analysis was performed using the log-rank test (p<0.05).    
3.2 Differential gene expression analysis. Using the EdgeR package in Rstudio, implementing the 
negative binomial distribution model, primary tumour HTSeq counts were input, and subsequently 
filtered for protein-coding genes, using the Biomart package as previously described [11, 12]. Expressed 
genes were defined as having at least 10 counts in at least 17 samples. The counts were normalized, 
dispersion estimated and differentially expressed genes (DEGs) were identified by Exact Test. The results 
were filtered using a false discovery rate (FDR) <0.05 and further analysed by receiver operating 
characteristics (ROC) and area under the curve (AUC) with p<0.05 as previously described using 
GraphPad Prism version 5 [13]. 
3.3 Biomarker discovery. Using the EdgeR package, a similar analysis was performed using the dnMBC 
sample and 113 normal tissue controls from the TCGA. Significant genes (as described above) were 
filtered using the secretome and serum proteome accessed from the Human Protein Atlas [14]. Biomarker 
sensitivity and specificity was summarized in receiver operating characteristics (ROC) curves and area 
under the curve (AUC) with p<0.05. 
3.4 Molecular subtype classification. Primary tumours were classified into molecular subtypes by the 
PAM50 signature as previously described using the genefu package in R studio and assessed for statistical 
significance using Fisher’s exact test [15, 16].  
3.5 Protein-protein interaction and Gene ontology analysis. Using STRING-DB, the significantly 
regulated genes were analysed for protein-protein associations using default settings; the main network of 










cluster was analysed for functional enrichment in Cytoscape v3.6.1 using STRING’s enrichment plugin 
[17]. Significant terms were defined as FDR<0.05. Enriched terms were assessed for net log2 fold change 
by summation of gene expression. Concomitantly, the gene list was queried through literature search for 
metastatic processes and their molecular mechanisms. 
3.6 Genomic alterations. Mutation data, copy number variation, and alteration-based survival data were 
accessed from the cBioPortal via the TCGA PanCancer Atlas. TCGA sample IDs from the downloaded 
tumour HTSeq counts data were matched to those in cBioPortal to obtain their corresponding genomic 
data which were then visualized by oncogrid [8, 18]. 
 
4. Results 
4.1 Clinical data. The mean ages of dnMBCs and rMBC were 61.2 + 4.69 (95%CI) and 56.6 +3.56 
(95%CI) respectively (Table 1). African American patients were more represented in rMBC (30.61% vs. 
17.65%). Caucasian patients were similarly distributed (67.35% vs. 58.85%). dnMBCs were more likely 
to be deceased (76.47% vs. 71.43%). In terms of diagnosis, 82.35% of dnMBCs vs 61.22% were 
diagnosed with invasive ductal carcinoma and 5.88% vs. 22.45% were diagnosed with invasive lobular 
carcinoma. None of the findings were statistically significant (Table 1). An additional table has been 
provided with details regarding clinical variables [see Additional file 1]. 
4.2 Survival analysis. From the onset of metastasis the overall survivals of patients with dnMBC vs. 
rMBC were 36.35 months and 12.10 months respectively (p=0.0241) with a hazard ratio (HR) of 0.503 
(95%CI = 0.277 to 0.914) (Fig. 1D). rMBC patient survival by metastasis free interval (MFI) >2 years 
was 24.32 months and showed no statistical difference to dnMBC survival (p=0.364). Relapse patients 
MFI< 2 years had a median survival of 10.9 months and comparing dnMBC to this group showed a 










comparing the MFIs of rMBC (<2 years vs. > 2 years) showed a statistical significance (p=0.0178) with 
HR = 2.427 (95%CI = 1.166 to 5.054). 
4.3 Pathological variables. dnMBC tumours (70.59% vs. 53.06%) were ER/PR+ (p=0.0452). They were 
more advanced in T staging; 29.41% vs. 4.08% are T4 (p=0.0313), more lymph node involvement; 
35.29% vs 16.33% are N3 (p=0.0465), more positive margins; 47.06% vs. 6.12% (p<0.001). decreased 
lymphocytic infiltrate; 6.17% vs 12.32% (p=0.0361), marginally increased tumour necrosis; 2.44% vs. 
1.99% (p=0.0297). Histologically, dnMBCs were less aggressive with fewer mitotic cells, more tubular 
structures, and lower nuclear grade. In terms of molecular subtype (Figure 1F,G), dnMBCs were more 
likely to be Her2+ (17.65% vs. 4.08%) and less likely to be Basal (17.65% vs. 28.57%).  Other non-
significant findings included tumour mass and stromal content (Table 1). An additional table is available 
with details regarding pathological variables [see Additional file 1].  
4.4 Gene expression analysis. 74 genes were up-regulated, and 57 down-regulated. Top 10 up-regulated 
genes were BCHE, UGT2B4, ZFP57, CALCR, BCL2L14, ARHGAP36, GPM6A, KRT4, CYP4F8, and 
CDC20B. Top 10 down-regulated genes were CHGA, PCSK1, GRIA1, TRH, KCNJ16, OLFM4, HDC, 
PI3, SIAH3, and BMP5. A complete list of DEGs has been provided [see Additional file 2]. Top 
performing genes by ROC and AUC analysis included PPFIBP2, GATD3A, ARC, and PWP2 (Figure 2).  
4.5 Protein-protein interaction and functional analysis. The DEG list was significantly enriched in 
protein-protein associations (PPI enrichment p-value =1.5e-14). In total 20 clusters were formed (Figure 
3) and tested for functional enrichment summarized in Additional file 3. Cluster 1 was enriched in genes 
involved in cell proliferation, inflammation via IL-17 and TNF, cancer pathways, cell adhesion and 
apoptosis signalling.  Cluster 2 and 3 were enriched in nervous system processes including neural 
projections, cAMP signalling and calcium signalling, synaptic vesicles transport and clatherin mediated 
endocytosis.  Cluster 6 was enriched in steroid biosynthetic processes. Cluster 8 was enriched in cell 










complete list of functional enrichments by cluster is available [see Additional file 3]. Mechanisms of 
metastasis by gene expression in dnMBC versus rMBC included up-regulation of filopodia formation, 
Rac1/cdc42 signalling, beta-catenin signalling and adherens junction dysregulation. In rMBC, up-
regulated genes were involved in MMP and urokinase plasminogen activator expression. Similarly-
regulated pathways included ERK1/2, PI3K/Akt, and FAK signalling. The complete list of genes 
involved in metastasis is available [see Additional file 4]. 
4.6 Copy number alterations and mutations.  Data from cBioPortal (Figure 4) showed that dnMBCs and 
rMBC shared the top 2 most frequently mutated genes: TP53 (37.50% vs. 34.69%); PIK3CA (31.25% vs. 
28.57%). dnMBCs were more likely to have a PTEN mutation (25.00% vs. 6.12%) as well as mutations 
resulting in USP32 fusion proteins (18.75% vs. 0.00%) as well as KMT2C (18.75% vs. 8.16%) and 
GATA3 (18.75% vs. 10.20%). dnMBCs also had increased copy number alterations, and mutations but 
not significantly more than rMBC. In terms of alteration-based outcomes, patients with rMBC harbouring 
PTEN or ARID4B alterations resulted in poor survival outcomes, with no statistical significance for 
dnMBC. In patients with dMBC, ABL2 and GATA3 alterations resulted in poor survival outcomes, with 
no significance in rMBC. Patients in both groups with TP53 or PI3KCA alterations revealed no 
significant survival differences. Patients with TP53 mutations were associated with increased tumour 
hypoxia scores across both groups. No alterations were detected in either groups for the following genes 
in known breast cancer syndromes, namely CHEK2, MLH1, MSH2, MSH6, PMS2, EPCAM, STK11. 
Three rMBC patients had mutations in NF1, three had BRCA1 mutations, one with BRCA2 mutation and 
one with an ATM mutation. One patient in the dnMBC group harboured a NF1 mutation. A complete list 
of copy number alterations and mutations used in this study is available [see Additional file 5].  
4.7 Biomarker analysis. 712 genes coding for experimentally confirmed secreted proteins were 
significantly up-regulated in dnMBCs compared to normal tissue controls. The top 5 genes were CBLN2, 










file 6]. Top performing genes include MMP11 (AUC of 1.00), followed by COL10A1 (AUC =0.9989), 
SCT (AUC=0.9908), and WISP1 (AUC=0.9900) (Figure 5).  
 
5. Discussion 
5.1 Study context. dnMBC is an interesting phenomenon given its steadily increasing incidence despite 
mammography screening and how it seems to challenge the Halstedian paradigm of BC tumour 
progression [3, 5]. In this work we have conducted the first gene expression study of these tumours, 
establishing a preliminary molecular portrait of this disease and have shown that there are indeed 
significant clinical, genomic, molecular and pathological differences between dnMBC and relapsing 
primary tumours, indicating that dnMBC may have distinct biology. Due to this study’s small sample 
size, largely resulting from limited primary tumour data, clinical consistency with the literature was 
important to improve its external validity. Significant findings that were recapitulated in this study 
included the increased hormone receptor positive status of dnMBC, higher nodal involvement, improved 
survival outcomes relative to rMBC, and the importance of the MFI for rMBC prognosis [19-21]. Non-
significant congruencies were increased age of metastasis for patients with dnMBC. The main non-
significant incongruencies included increased diagnosis of IDC in dnMBCs and increased frequency of 
African American patients in rMBCs.  It should also be noted that while on average dnMBC survival 
outcomes are better than those in relapsed patients, recent publications have shown conflicting evidence 
for the role of systemic therapy in terms of patient survival between these tumour groups. One study 
found that in patients having undergone systemic therapy, dnMBCs have a better prognosis than rMBC 
regardless of MFI (greater or less than 24 months) [22]. However, another study showed similar outcomes 
between dnMBC and rMBC with MFI >24 months regardless of use of systemic (neo)adjuvant therapy 
[21]. In using samples from the TCGA, none of this study’s patients received neo-adjuvant therapy and 
their clinical outcomes are more comparable with the findings in the latter of the aforementioned studies. 










MFI for survival in rMBC, however this study’s data regarding systemic therapies after tumour resection 
is too limited to comment on (Table 1). 
5.2 dnMBC expresses more therapeutic targets than rMBC. According to the National Institute for Health 
and Care Research (NICE) guidelines, in cases of advanced breast cancer, treatment is guided by tumour 
histology. Histology focuses on important therapeutic targets, namely the oestrogen receptor, 
progesterone receptor and human epidermal growth factor receptor (Her2/ Erbb2). In this study dnMBC 
were more likely to be HR+ and Her2+ than rMBC, thus increasing the role of endocrine therapy 
(Tamoxifen/ Anastrazole) and epidermal growth factor targeting therapy (Trastuzumab and Lapatinib) in 
this treatment naïve subgroup. Furthermore, in advanced breast cancer, both HR and Her2 are associated 
with improved survival, though the benefits of Her2 expression appear to be unrelated to its use as a 
therapeutic target [21, 23, 24]. Contrarily, rMBC was more likely to be Basal in molecular subtype and 
triple negative histologically which are known to be more aggressive tumours with poor survival 
outcomes [25]. 
5.3 Genomic alterations have group-specific effects on patient outcomes. In assessing the genomic 
landscape of these tumours, we uncovered that PTEN, a tumour suppressor phosphatase and tensin 
homolog, was more frequently mutated in dnMBC [26]. Since PTEN loss is a known tumourigenic event 
in BC with prognostic implications, we examined the effects of its alteration in each group on patient 
survival [27]. Interestingly, despite the increased presence of PTEN mutations and similar levels of 
deletions, PTEN alterations had no significant prognostic effect on patients with dnMBC, however in 
rMBC a PTEN alteration appeared to be a devastating prognostic event (Figure 4D). This finding led us to 
examine more gene alterations for group-specific survival effects and discuss their implications. In terms 
of the main offenders in breast cancer, TP53 and PIK3CA alterations showed no survival differences in 
either group. ARID4B, a gene interacting with chromatin modifying complexes and associated with 
metastasis in BC, was shown to be more frequently amplified in rMBC with poor survival outcomes [28]. 










were not significantly affected by these gene alterations (Figure 4D). GATA3 is a transcription factor that 
regulates normal breast morphology and is correlated with the expression of ER [29]. While there is 
debate over the role of this gene in BC, it has been hypothesized that mutations in GATA3 in ER+ 
tumours may alter ER turnover and enhance ER and GATA3-driven tumour growth [29]. Conversely, 
wild-type GATA3 expression can also repress Basal tumour progression which is a possible explanation 
for why we observe GATA3 mutations in rMBC with similar patient outcomes [29]. 
5.3 dnMBCs down-regulate immune infiltration. Transcriptomic analysis and functional enrichment of 
protein clusters revealed that dnMBCs down-regulate chemotaxis, TNFa, interleukin-17 (IL-17) 
signalling and the inflammatory response which is consistent with the significant histological finding of a 
2-fold decrease in tumour-infiltrating lymphocytes (TILs). Previous studies have discussed the role of the 
immune response to chemotherapy in the poor outcomes of rMBC [22]. In this study, even before 
systemic therapy, a significant increase in TILs was observed which may indicate that even in primary 
lesions, patients with rMBC may be primed for a tumourigenic response to such therapies through its pro-
inflammatory biology. In murine breast cancer models, it has been demonstrated that TILs, particularly T-
cells that secrete IL-17, promote a pro-tumorigenic and pro-inflammatory environment that results in 
increased tumour proliferation, angiogenesis, and increased expression of matrix metallopeptidase 9 
(MMP9) which degrades the extracellular matrix (ECM), thus promoting invasion and metastasis [30]. 
Interestingly, all these aforementioned factors were enriched in rMBC for Cluster 1, indicating that 
immune-mediated tumour progression may be a significant differentiating pathway to metastasis between 
these two tumour groups. And indeed, when the gene list was queried for molecular mechanisms of 
metastasis, rMBC showed increased proclivity for ECM degradation, targeting both urokinase 
plasminogen activator (uPA) and MMP expression. Additionally, MMP9 expression was found to be up-
regulated in rMBC and PTEN mutations were 4 times more common in dnMBC and have been 










5.4 dnMBCs up-regulate steroid biosynthesis with implications for endocrine therapy. Steroid signalling 
is well-characterized feature that drives ER/PR+ breast cancer [32]. In keeping with their significantly 
increased ER/PR+ histology, dnMBCs showed net up-regulation in cholesterol/steroid synthetic processes 
in Cluster 6. One of the up-regulated genes, namely HSD17B7 is known to be induced by oestrogen 
receptor alpha (ERa) and drives tumourigenesis through a feedforward mechanism involving the 
production of intratumoural oestradiol from weaker steroids oestrogen and oestrone [33]. MSMO1, 
another gene involved in cholesterol biosynthesis was also shown to be up-regulated in ER+ BC cell lines 
and whose increased expression was associated with resistance to aromatase inhibitors [34]. While 
dnMBCs are more likely to be ER+ than rMBC they also express genes involved in endogenous steroid 
production and aromatase inhibitor resistance which has implications for endocrine therapy. One study 
demonstrated the importance of systemic therapy (including endocrine therapy) in dnMBC survival, 
without which the survival benefit is lost relative to rMBC which implicates unrestrained steroid 
signalling in dnMBC tumour progression [22].   
5.5 dnMBCs harness the cytoskeleton and disrupt cell adhesion to promote invasion and metastasis.          
A prominent theme among the genes involved in dnMBC metastasis mechanisms is the interconnectivity 
between filopodia assembly dynamics, Rac1/cdc42, beta-catenin, and adherens junctions, namely Wnt 
signalling. Canonical Wnt signalling leads to nuclear localization of beta-catenin which in normal 
epithelium is in close approximation to the cell membrane where it stabilizes cell-cell adhesion via E-
cadherin [35]. Displacement of beta-catenin from adherens junctions destabilizes them and decreases 
epithelial integrity—an essential step to epithelial mesenchymal transformation (EMT). Additionally, 
Rac1 promotes the nuclear localization of beta-catenin and also regulates filopodia formation through 
actin dynamics in non-canonical Wnt signalling [36]. Wnt11 (up-regulated in dnMBC) has been shown to 
activate both canonical and non-canonical Wnt pathways, possibly combining the EMT-promoting effect 
of nuclear beta-catenin through canonical Wnt signalling with metastasis-promoting actin regulation via 










reinforced this concept in demonstrating that Wnt1 depletion caused actin disorganization, decreased 
Rac1 expression and interfered with filopodia function and decreased the cancer stem cell’s migratory 
potential [38, 39]. This relative dependence on cytoskeletal dynamics indicates that dnMBCs may be 
more sensitive to cytoskeletal-targeting therapies such as taxanes which are commonly used in the 
treatment of advanced breast cancer and may contribute to their improved survival outcomes as supported 
by a previous study highlighting the importance of systemic therapy for improved dnMBC survival [22]. 
Conversely, rMBC tumour cells may rely more heavily on ECM degradation to propagate rather that 
cytoskeletal activity. Current therapies for systemic disease do not specifically target cancer cell’s 
enzymatic degradation of the ECM, which is associated with most aggressive form of breast cancer, 
namely triple negative (histological) or basal (molecular) subtypes which are overrepresented in rMBC. 
These findings are also consistent with patient survival outcomes. Interestingly, development of treatment 
resistance was previously hypothesized to be the cause of poor survival in rMBC, however, in this study 
we have preliminary evidence that even in the primary stage, tumours of rMBC are more likely to be 
basal, accompanied by a less targetable mechanism of progression and metastasis compared to dnMBC. 
5.6 Mammography and dnMBC. Though the tumour sizes for this study were missing, a recent study 
using Surveillance, Epidemiology, and End Results (SEER) data demonstrated that dnMBC primary 
lesions tend to be larger than stages I-III tumours which are routinely detected mammographically, 
indicating that tumour size is not likely to be the limiting factor regarding mammography detection [5]. 
Rather, it has been postulated that dnMBC can grow rapidly and metastasize between mammograms, 
making the disease difficult to detect, and tending to occur in populations with limited access to 
screening, namely, African American women, and those of low socioeconomic and educational status  
[5]. However, this would appear biologically discordant. Despite their rapid development, dnMBC 
primary lesions appear less aggressive than their rMBC counterpart, yet have significantly increased 
tumour T staging, indicating that despite lower mitotic bodies, lower nuclear grade, and relatively 










skin or chest wall, relative to primary tumours of rMBC patients. An explanation for this 
clinicopathological discrepancy is that these tumours may have experienced a period of rapid growth 
followed by a plateau at the time of resection according to a logistic or Gompertz model of tumour growth 
[40]. This finding is intriguing, especially when matched with the increased incidence of PTEN mutations 
which are associated with increased tumour size, increased tumour stage, poor differentiation and poor 
clinical outcomes [27, 41]. Additionally, Harding and Welch have noted that while the incidence of small 
tumours has increased, the incidence of large tumours has not proportionately decreased, indicating that 
improved screening is not detecting most of these large tumours in earlier stages [42, 43]. Furthermore, 
Welch and colleagues noted that in countries with limited BC screening, the incidence of dnMBC is 
similar indicating that their size and presentation are likely reflective of their unfavourable biology [3, 5]. 
The question then becomes, is dnMBC an inevitable product of tumour biology, or does a window exist 
where these tumours can be detected and treated before metastasis? Is the answer more screening or is 
screening doing more harm if biology rather than early detection dictates patient survival? 
5.7 dnMBCs express sensitive and specific secreted protein biomarkers. Serum biomarkers have long 
been sought for breast cancer and are currently in their early phase of development [44-46]. With the 
limitations of BC screening in the context of dnMBC, we searched for adjunct screening methods for this 
disease in the form of serum biomarkers. Here we produced a panel of previously confirmed secreted 
proteins that are sensitive and specifically expressed by dnMBC. Interestingly, some of the biomarkers 
discovered here have been detected in sera of patients for breast cancer, namely PLAC1, FN1 (FN), 
EDIL3 (DEL1), TFF1, TFF3, AGR2, AGR3, APOC1, and PTN, though they do not reach the high AUC 
values (>0.99) that our top-performing biomarkers exhibit [45, 46]. To further validate our candidates, 
protein expression studies in patient plasma will need to be undertaken. However, even if successful, the 
biomarkers will be of little use if outreach and healthcare access are not improved for the low 












In this study, we established a preliminary molecular landscape of dnMBC versus rMBC primary tumours 
to further understand how they differ and revealed some significant biological insights. dnMBC appears 
to be less aggressive than rMBC despite its early metastatic potential; this is supported by patient 
survival, histological grading, molecular subtyping and by our molecular model. Briefly, dnMBC showed 
increased proclivity for cytoskeletal regulation, was more steroid dependent, and recruited fewer 
lymphocytes, while rMBC was more immunogenic, more likely to be triple negative and targeted the 
ECM more frequently. Ultimately the limitations of mammography with respect to dnMBC may be 
compensated for through the addition of sensitive and specific serum biomarker screening that will 
prompt further diagnostic imaging; the candidates we discovered in this study would require further 
validation in patient serum. Lastly, due to this study’s small sample size, we encourage further research 
into the molecular properties of these primary tumours, as well as their metastatic counterparts, to further 
characterize the molecular differences between them which may have important implications for therapy 
and tumour detection. 
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Additional Files 
Additional file 1: Patient and tumour characteristics. Table consisting of TCGA patient IDs clinical 
variables including age, gender, ethnicity and survival, as well as pathological variables including, 
diagnosis, histochemistry, PAM50, etc. 
Additional file 2: Differentially expressed genes dnMBC vs. rMBC: Complete table of 131 differentially 
expressed genes, showing the gene’s Ensembl ID, followed by gene name, log fold change, log(counts 
per million), p-value and FDR.  
Additional file 3: Gene ontology analysis. Table of 20 gene clusters with additional details regarding 
enriched GO terms, number of genes involved, FDR, net regulation, etc.      
Additional file 4: Mechanisms of metastasis. Table of DEGs with known involvement in mechanisms of 
metastasis, showing gene name, category, mechanism, reference and tabulation of the genes below. 
Additional file 5: CNA and mutations. Table providing details of copy number alterations and mutations 










Additional file 6: Differentially expressed genes dnMBC vs. normal tissue: Complete table of 1228 
differentially expressed, secreted genes, showing the gene’s Ensembl ID, followed by gene name, 
whether that gene is present in normal human plasma, log fold change,  log(counts per million), p-value 
and FDR.  
 
Figure Legends 
Figure 1: Clinicopathological characteristics of dnMBC vs. rMBC. (A,C) PAM50 molecular classification 
of tumours showing increased Her2 and less Basal tumours in dnMBC. (B) Patient age boxplot showing 
similar age distributions. (D,E) Patient overall survival from onset of metastasis indicating that dnMBC 
patients have a better prognosis. (F,G) Tumour histology from the TCGA showing low grade versus high 
grade tumours respectively and (H-K) histological characteristics that contribute to histological grade 
showing that dnMBCs have a lower grade. (L) Plot of lymphocytic infiltrate tumour fraction with 
decreased infiltration in dnMBC. (M) Tumour T-staging profile with significantly elevated T staging in 
dnMBC.     
 
Figure 2: Differential gene expression analysis of dnMBC vs. rMBC. (A) Hierarchical clustering of top 
performing DEGs showing clustering of dnMBC. (B-E) LogCPM expression and AUC performance of 
the top 4 DEGs which have unknown roles in breast cancer. (F,G) Principal component analysis of the top 
performing DEGs showing segregation of tumours.   
 
Figure 3: Gene ontology analysis and comparative metastasis mechanisms. (A) Main clusters (1-20) of 
core DEGs in PPI-interaction network. (B) Gene ontology terms by cluster with FDR and log fold change 










Molecular model of metastasis highlighting main differences by gene expression, including filopodia 
assembly, MMP activation/ expression, Rac1 signalling and cell adhesion. (D) Mechanisms of metastasis 
by gene expression.  
 
Figure 4: Oncogrid and alteration-specific survival of dnMBC vs rMBC. (A) Oncogrid displaying tumour 
mutations, copy number alterations and hypoxia scores. (B) Comparison of most frequently mutated 
genes, namely TP53, PIK3CA, PTEN, USP32, and KMT2D. (C) Comparison of copy number variations 
between groups. (D) Differing effects of gene alterations in PTEN, ARID4B, ABL2, and GATA3 on 
overall patient survival in dnMBC and rMBC. 
 
Figure 5: Biomarker discovery analysis. (A) Unsupervised hierarchical clustering of DEGs between 
Normal breast tissue and dnMBC showing clustering of tumour and normal tissue. (B-E) Expression and 
ROC analysis for top performing biomarker candidates: MMP11, COL10A1, SCT, and WISP1. (F,G) 











Table1 Clincopathological characteristics 
 
dnMBC (n = 17) rMBC (n = 49) Exact test T test 
Characteristics Number Percentage Number Percentage p-value p-value 
Age         0.147 -- 
 <50 2 11.76% 17 34.69% 
   50–64 11 64.71% 20 40.82% 
   65+ 4 23.53% 12 24.49% 
  Age at metastasis         -- 0.436 
 
61.24 -- 58.88 -- 
  Year of diagnosis         0.65   
   1990-2000 2 12.50% 3 6.12% 
     2000-2010 3 18.75% 12 24.49% 
     >2010 12 75.00% 33 67.35% 
     Unknown 0 0.00% 1 2.04% 
  Diagnosis         0.364 -- 
   IDC 14 82.35% 30 61.22% 
     ILC 1 5.88% 11 22.45% 
     Mucinous 0 0.00% 1 2.04% 
     Mixed 1 5.88% 3 6.12% 
     Unknown 1 5.88% 4 8.16% 
  Tumor stage         n/a -- 
   I -- -- 3 6.12% 
     II -- -- 22 44.90% 
     III -- -- 24 48.98% 
  Tumour Size         3.13E-02 -- 
   T1 1 5.88% 7 14.29% 
     T2 6 35.29% 28 57.14% 
     T3 4 23.53% 11 22.45% 
     T4 5 29.41% 2 4.08% 
     Unknown 1 5.88% 0 0.00% 
  Node status         4.65E-02 -- 
   N0 0 0.00% 7 14.29% 
     N1 3 17.65% 24 48.98% 
     N2 4 23.53% 10 20.41% 
     N3 6 35.29% 8 16.33% 
     Unknown 4 23.53% 0 0.00% 
  Histology         0.22 -- 
   ER+/PR+ 12 0.67 26.00 0.51 
     ER-/PR- 0 0.00 9.00 0.18 
     Her2+ 1 0.06 2.00 0.04 
     Triple neg. 1 0.06 7.00 0.14 
     Unknown 4 0.22 7.00 0.14 










   Positive 12 70.59% 26 53.06% 
     Negative 1 5.88% 16 32.65% 
     Unknown 4 23.53% 7 14.29% 
  Her2 Status         1 -- 
   Positive 1 5.88% 2 4.08% 
     Negative 12 70.59% 26 53.06% 
     Unknown 4 23.53% 21 42.86% 
  Histological Grade         0.0856   
   Grade I 1 5.88% 3 6.12% 
     Grade II 6 35.29% 4 8.16% 
     Grade III 5 29.41% 20 40.82% 
     Unknown 5 29.41% 22 44.90% 
  Tumor Mass         0.099 -- 
   <300 3 17.65% 14 28.57% 
     300-600 8 47.06% 24 48.98% 
     600-900 5 29.41% 3 6.12% 
     >900 1 5.88% 7 14.29% 
     Unknown 0 0.00% 1 2.04% 
  PAM50 type         0.481 -- 
   Luminal A 4 23.53% 12 24.49% 
     Luminal B 6 35.29% 17 34.69% 
     Her2 3 17.65% 2 4.08% 
     Basal 3 17.65% 14 28.57% 
     Normal 1 5.88% 4 8.16% 
  Tumour Infiltrate             
   Leukocytes -- 16.05% -- 23.74% -- 0.165 
   Macrophages -- 8.41% -- 9.74% -- 0.351 
   Lymphocytes -- 6.17% -- 12.32% -- 3.61E-02 
   Neutrophils -- 0.05% -- 0.06% -- 0.588 
   Mast cells -- 0.93% -- 1.15% -- 0.394 
   Dendritic cells -- 0.50% -- 0.47% -- 0.101 
   Eosinophils -- 0.00% -- 0.00% -- n/a 
Margin status         7.41E-05 -- 
   Positive 8 0.47 3.00 0.06 
     Negative 6 0.35 42.00 0.86 
     Close 2 0.12 2.00 0.04 
     Unknown 1 0.06 2.00 0.04 
  Tumour necrosis         -- 2.97E-02 





  Tumor stromal cells         -- 0.229 





  Site of Metastasis         -- -- 
    Bone 2 10.53% 33 63.46% 











    Lung 1 5.26% 11 21.15% 
      Liver 1 5.26% 1 1.92% 
      Skin 0 0.00% 2 3.85% 
      Cervical node 0 0.00% 1 1.92% 
      Mediastinal nodes 0 0.00% 2 3.85% 
      Unknown 14 73.68% 0 0.00% 
  Systemic therapy     -- -- 
    Neo-adjuvant 0 0.00% 0 0.00%   
    Adjuvant 3 17.65% 2 4.08%   
    None 1 5.88% 0 0.00%   
    Unknown 13 76.47% 47 95.92%   
Ethnicity         0.664 -- 
    Black 3 17.65% 15 30.61% 
      White 10 58.82% 33 67.35% 
      Unknown 4 23.53% 1 2.04% 
  Vital status         0.762 -- 
 Living 4 23.53% 14 28.57% 
   Deceased 13 76.47% 35 71.43% 
  MFI             
    <6 months -- -- 3 6.12% 
      6 months - 2 years -- -- 24 48.98% 
      >2 years -- -- 22 44.90% 
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 From the onset of metastasis, de novo metastatic breast cancer (dnMBC) patients have increased 
median survival compared to their relapsed counterparts (rMBC). 
 Relative to rMBC, dnMBC primary tumours display an immune evasion phenotype in their 
transcriptomes with significantly reduced tumour infiltrating lymphocytes histologically. 
 Genomic alterations in PTEN, GATA3, ABL2 and ARID4B have differential effects on patient 
survival in dnMBC vs. rMBC.  
 dnMBC tumours express sensitive and specific biomarkers that may be detectable in patient 
serum.  
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